Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to Rare Pediatric Disease Priority Review Voucher Program reauthorization; Issues related to H.R. 1262 / S. 3302 - Mikaela Naylon Give Kids a Chance Act of 2025; Issues related to the Consolidated Appropriations Act, 2026 (P.L. 119-75), including the extension of authority to issue priority review vouchers to encourage treatments for rare pediatric diseases; Issues related to the biotech ecosystem, including most-favored-nation drug pricing; Issues related to PBM reform, PAHPA reauthorization; and PDUFA reauthorization.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
HEALTHCARE DISTRIBUTION ALLIANCE via AKIN GUMP STRAUSS HAUER & FELD
2026 · third_quarter · Q3
Issues related to distributor-supported service models and related policy, including pharmacy services administrative organizations and management services organizations.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZELIS HEALTHCARE CORPORATION via AKIN GUMP STRAUSS HAUER & FELD
2026 · third_quarter · Q3
Source: Senate LDA
Issues related to Substance Use Disorder programs; Issues related to SUPPORT for Patients and Communities Reauthorization Act of 2025 (P.L. 119-44) funding; Issues related to H.R. 2509/S. 931 - COMPLETE Care Act; Issues related to behavioral health; Issues related to the Substance Abuse and Mental Health Services Administration's mental health and addiction treatment locator, FindTreatment.gov, and including quality indicators for addiction treatment.
Patients Deserve Price Tags Act
Client: ZELIS HEALTHCARE CORPORATION · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to healthcare payments, healthcare Transparency in Coverage regulations and legislation including S.2355/H.R.5582 - Patients Deserve Price Tags Act.
Patients Deserve Price Tags Act
Client: ZELIS HEALTHCARE CORPORATION · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to transparency in healthcare coverage, including H.R. 5582/S. 2355 - Patients Deserve Price Tags Act.
Patients Deserve Price Tags Act
Client: ZELIS HEALTHCARE CORPORATION · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to healthcare payments, healthcare Transparency in Coverage regulations and legislation including S.2355/H.R.5582 - Patients Deserve Price Tags Act.
Patients Deserve Price Tags Act
Client: ZELIS HEALTHCARE CORPORATION · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to transparency in healthcare coverage, including H.R. 5582/S. 2355 - Patients Deserve Price Tags Act.
Mikaela Naylon Give Kids a Chance Act of 2025
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to Rare Pediatric Disease Priority Review Voucher Program reauthorization; Issues related to H.R. 1262 / S. 3302 - Mikaela Naylon Give Kids a Chance Act of 2025; Issues related to the Consolidated Appropriations Act, 2026 (P.L. 119-75), including the extension of authority to issue priority review vouchers to encourage treatments for rare pediatric diseases; Issues related to the biotech ecosystem, including most-favored-nation drug pricing; Issues related to PBM reform, PAHPA reauthorization; and PDUFA reauthorization.
Issues related to Substance Use Disorder programs; Issues related to SUPPORT for Patients and Communities Reauthorization Act of 2025 (P.L. 119-44) funding; Issues related to H.R. 2509/S. 931 - COMPLETE Care Act; Issues related to behavioral health; Issues related to the Substance Abuse and Mental Health Services Administration's mental health and addiction treatment locator, FindTreatment.gov, and including quality indicators for addiction treatment.
Issues related to healthcare payments, healthcare Transparency in Coverage regulations and legislation including S.2355/H.R.5582 - Patients Deserve Price Tags Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE DISTRIBUTION ALLIANCE via AKIN GUMP STRAUSS HAUER & FELD
2026 · third_quarter · RR
Issues related to distributor-supported service models and related policy.
ZELIS HEALTHCARE CORPORATION via AKIN GUMP STRAUSS HAUER & FELD
2026 · second_quarter · Q2
Issues related to transparency in healthcare coverage, including H.R. 5582/S. 2355 - Patients Deserve Price Tags Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
SHATTERPROOF via AKIN GUMP STRAUSS HAUER & FELD
2026 · second_quarter · Q2
Issues related to Substance Use Disorder programs; Issues related to SUPPORT for Patients and Communities Reauthorization Act of 2025 (P.L. 119-44) funding; Issues related to H.R. 2509/S. 931 - COMPLETE Care Act; Issues related to behavioral health; Issues related to the Substance Abuse and Mental Health Services Administration's mental health and addiction treatment locator, FindTreatment.gov, and including quality indicators for addiction treatment.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via AKIN GUMP STRAUSS HAUER & FELD
2026 · second_quarter · Q2
Issues related to Rare Pediatric Disease Priority Review Voucher Program reauthorization; Issues related to H.R. 1262 / S. 3302 - Mikaela Naylon Give Kids a Chance Act of 2025; Issues related to the Consolidated Appropriations Act, 2026 (P.L. 119-75), including the extension of authority to issue priority review vouchers to encourage treatments for rare pediatric diseases; Issues related to the biotech ecosystem, including most-favored-nation drug pricing; Issues related to PBM reform, PAHPA reauthorization; and PDUFA reauthorization.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE